Simulations Plus, Inc. (Nasdaq: SLP), a global leader in model-informed and AI-accelerated drug development, has announced it will report its first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026. The company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. The event is open to investment professionals, current shareholders, and prospective investors. Participants can join the live webcast by registering through the company’s investor relations website or by dialing into the call using the numbers provided: 1-877-451-6152 (U.S. and Canada) or 201-389-0879 (international). A Call me™ link is also available for those who wish to request a return call. The webcast will be accessible on the Simulations Plus investor relations page at www.simulations-plus.com/investors/corporate-profile/corporate-profile/, where it will be available for replay approximately one hour after the live session ends. This allows broader access for those unable to attend in real time. Simulations Plus specializes in advancing biopharmaceutical innovation through science-based software and consulting solutions that accelerate drug discovery, development, and commercialization. The company leverages cutting-edge modeling and artificial intelligence to deliver data-driven insights that improve decision-making across the pharmaceutical lifecycle. Its platforms support pharmacokinetics, pharmacodynamics, clinical trial simulation, and regulatory submissions, enabling clients to reduce development timelines and costs while improving success rates. The company’s commitment to innovation extends beyond technology. Simulations Plus emphasizes Environmental, Social, and Governance (ESG) principles, focusing its efforts on areas where it can generate the greatest positive impact. The company continues to prioritize sustainability, ethical practices, diversity, and transparency in its operations and strategic initiatives. This earnings call comes amid growing demand for AI-powered tools in drug development, driven by the need for faster, more efficient, and cost-effective approaches to bringing new therapies to patients. Simulations Plus has positioned itself at the forefront of this transformation, partnering with pharmaceutical giants, biotech startups, and regulatory agencies worldwide. The announcement underscores the company’s ongoing momentum and its role in shaping the future of model-informed drug development. As the industry increasingly adopts AI and computational modeling, Simulations Plus is well-placed to support clients through complex development challenges, from preclinical research to post-approval monitoring. Investors and industry observers will be particularly interested in the company’s financial performance, growth in software and consulting revenue, new product launches, and strategic partnerships. The Q1 2026 results are expected to reflect the company’s ability to scale its AI-driven solutions and expand its global footprint. Simulations Plus has a strong track record of innovation and client success, and this upcoming call offers a key opportunity to assess its performance in a rapidly evolving market. The company’s focus on responsible AI, scientific excellence, and long-term value creation continues to set it apart in the biopharma technology space. For more information, including details on the company’s ESG initiatives and recent developments, visit www.simulations-plus.com. The full press release and additional news from Simulations Plus, Inc. are available on the company’s website.